Pain Management 2004 - Analysing Regulatory, Commercial & Pharmaceutical Practices

===========================================================
PAIN MANAGEMENT 2004
Analysing Regulatory, Commercial & Pharmaceutical Practices
8th and 9th September 2004 (Workshop 7th September 2004)
Marriott Kensington Hotel, London
===========================================================

**FULL AGENDA BELOW** - PDF COPY OF THE BROCHURE NOW AVAILABLE

Visiongain b2b Conferences is pleased to announce that 'Pain Management 2004 - Analysing Regulatory, Commercial & Pharmaceutical Practices ' will be run in early September this year. This event will follow up on the success of 'Future Pain Drugs 2003' but as a case-study based event will focus more on future targets and market development. The agenda is now complete, a list of confirmed speakers and topics can be found below. 

KEY THEMES:

**Identify Key Market Segments and Profit From Emerging Trends in Pain Therapeutics 
**Clinical Models for Pain- Learn Which Will Suit Your Company Needs 
**Discover How Drug Delivery Systems will Shape the Future of Pain Therapeutics, Highlighting Lucrative Market Opportunities
**Learn From the Best Practice Case Studies such as: Actiq- SPM 927- GPI 5693- Vioxx- Sativex- Prialt
**Examine the Key Legal and Regulatory Issues in the Development of Novel Pain Therpaeutics  
**Assess the Advances in Cannabis Based Medicines- R&D and Delivery Technologies

KEY SPEAKERS

**Dr Peter McIntyre, Lab Head/ Head of Exploratory Pain Projects, Novartis
**Dr Sharon Bingham, Somatic Pain - Pain Research, Neurology CEDD, GlaxoSmithKline
**Gary Liversidge, Senior Director, Project Planning and Management, Elan
**Dr George Miljanich, Research Fellow, Elan Pharmaceuticals
**Praveen Anand, Professor Clinical Neurology, Imperial College
**Dr Stuart Bevan, Director, Novartis Institute for Medical Research
**Dr Jeffry Vaught, Senior Vice President & President, R&D Division, Cephalon
**Dr Christine Rauschkolb, Program Director/ Medical Scientist Pain, Schwarz Bioscience
**Dr Tony Ho, Associate Director, Merck
**Dr Mike Reed, Director Branded Product Marketing International, Alpharma
**Dr Krystyna Wozniak, Lead Scientist on NAALADase program, Guilford Pharmaceuticals Inc
**Dr Stephen Wright, Director of R&D, GW Pharma Ltd
**Dr Francesco Impagnatiello, Pharmacologist- Pain Research, NicOx

WHO SHOULD ATTEND

-Medical Director
-Divisional VP, Neurological & Urological
-Pain, Migraine Research
-Divisional VP, Immunosciences Development
-Inflammatory Therapeutics
-Respiratory RA Disease Group
-Head of clinical development/ VP clinical development
-Head of clinical research, CNS
-Head of R&D (Pain/CNS/Depression)
-CNS clinical project management
-Head of CNS therapeutics
-Chief Technical Officer
-Director, Preclinical R&D
-Vice President, Research
-Vice President, Research and Development

2003's TESTIMONIALS

"interesting topics, well organised"  
"excellent conference" 
"very good, covering a wide aspect of pain therapy" 
"topline overview of the field" 
"topical + scientifically sound" 
"exceeded expectations, high scientific level" 

---------------------
DELEGATE REGISTRATION
---------------------

Places at this event are limited, please call or email me now to secure your place

- PRICING -
Attend the:
** Conf. + pre conf. workshop GBP 1600.00 Plus VAT 
** Conference only Fee: GBP 1299.00 Plus VAT
** Pre conference workshop only Fee: GBP 650.00 Plus VAT 

- BOOKINGS -
Booking is easy, simply contact Harry Grant on:
Telephone: +44 (0)20 8767 6711
Fax: +44 (0)20 8767 5001
Email: mailto:[email protected]
Terms and conditions apply - see below.

Regards,

Harry Grant
Account Manager 
Visiongain b2b Conferences 
Tel: +44 (0) 20 8767 6711 
http://www.b2b-conferences.com
mailto:[email protected] 


==============================================================================================
-----------------
** FULL AGENDA **
-----------------

PRE-CONFERENCE INTERACTIVE WORKSHOP
Tuesday 7th September 2004; 10am - 2pm

DISCOVERING THE IDEAL ANALGESIC - BARRIERS IN PRECLINICAL DISCOVERY
Led by: Dr. Jenny Longmore, Freelance Consultant

-The ideal analgesic - one pill fits all?
-Species differences
-Neuropathic pain - lessons from migraine?
-Are animal assays relevant or validated?
-Brain penetration - desirable or necessary?


=====================================
Day One Wednesday 8 th September 2004
=====================================

09:00 Registration and coffee

09:30 Opening remarks from the Chair

MODELS AND TARGETS

09:40 Developments in Pain Therapy- Ventures for Your
Company
* Molecular targets in pain research
  - past, present and future
* Research methodologies- how can you implement them?
* Balancing risk in the research portfolio
  - gain positive results for your company
* Outlook: new targets for pain relief ligands and the future for
  pain therapies in the clinic

Dr. Peter McIntyre
Lab Head/ Head of Exploratory Pain Projects
Novartis

10:20 Human Pain Models- How Can You Maximise Their Use?
* Limitations of current animal models
  - find how they relate to human data
* Clinical needs- pathophysiological and imaging surrogates
* Lessons to learn from failed clinical trials
  - gain knowledge on avoiding and overcoming similar
  problems
* How to increase the success of Phase II clinical trials
* Target validation: novel pain targets in human chronic states

Praveen Anand
Professor Clinical Neurology
Imperial College

11:00 Morning Coffee

11:20 How to Use Nitric Oxide (NO) Properties to Achieve
Effective Therapeutics
* NO-releasing analgesics: a novel class of drugs for the
  treatment of pain
* How the NO-releasing moiety can contribute to commonly-used
  analgesics: rationale and potential added values
* Case Studies: NO-releasing paracetamol and NO-releasing
  gabapentin
* Potential mechanisms of action of NO in pain/inflammation

Dr. Francesco Impagnatiello
Pharmacologist- Pain Research
NicOx

12:00 The World Pain Market
* A World over view of the drugs used in pain relief
* The World Neuropathic Pain Market
* The World Chronic Pain Market
* The World Opioid Market
* The World Inflammatary Market
* New Directions

Dr. Ray Scraggs
Pharmaceutical Consultant
visiongain Consultancy

12:40 Lunch

14:00 Using Animals- How to make them Disease Relevant
Pain Models?
* Classical versus novel approaches to pain models- what will
  suit your needs?
* Changing views on behavioural versus functional endpoints
* How you can validate a model- pointers
* Difficulties in assessing pain in animals- how effective are
  these models and how to improve them
* Screening putative analgesics

Dr. Sharon Bingham
Somatic Pain - Pain Research, Neurology CEDD
GlaxoSmithKline

14:40 The Role of Vanilloid Receptors in Nociception
* Expression of vanilloid receptors
  - how to demonstrate the existence of specific vanilloid
  receptors
* Molecular and functional characterisation of cloned VR1
* VR1 as a pivotal transducer
* Comparison of VR1 and native receptors- what advantaged
  can you make use of?

Dr. Stuart Bevan
Director
Novartis Institute for Medical Research

15:20 Afternoon Tea

OVERCOMING CANCER PAIN

15:40 CASE STUDY: Actiq, the only FDA Approved Drug for
Breakthrough Cancer Pain
* Temporal characteristics of persistence and breakthrough pain
* Actiq's novel oral transmucosal system- how does it work?
* Parmacokinetics and pharmacodynamics of oral transmucosal
  fentanyl delivery
* What are the benefits of oral transmucosal delivery?

Dr. Jeffry Vaught
Senior Vice President & President, R&D Division
Cephalon

NEUROPATHIC PAIN MARKET

16:20 CASE STUDY: PRIALT (ziconotide), a Non Opioid
Analgesic for Severe Chronic Pain
* NCCB: PRIALT's novel mechanism of action
* N-type calcium channel blockade --implications
* Non-clinical profile: important differences between PRIALT and
  morphine
* Phase III clinical studies: efficacy in opiate failures
* Mechanisms of action of PRIALT, morphine, and gabapentin

Dr. George Miljanich
Research Fellow
Elan

17:00 Questions and Discussion

17:20 Chairman summation

17:30 Close of Day One

====================================
Day Two Thursday 9 th September 2004 
====================================

09:00 Registration and Coffee

09:30 Opening remarks from the Chair

09:40 CASE STUDY: Pharmacology of SPM 927 and its
Relevance to Clinical Practice
* Basic pharmacology of SPM 927
* Efficacy of SPM 927 in an animal model for diabetic
  neuropathy
* Pharmacological profiling in further animal models for chronic
  pain- what can you impliment in practice?
* This anti-convulsant drug's mechanism of action

Dr. Bettina Beyreuther
Senior Scientist Pharmacology- Preclinical Development
Schwarz BioSciences

10:20 CASE STUDY: SPM 927 - A Novel Promising Pain Treatment
* Human pharmacology of SPM 927
* 'First in patient' evaluation- where can improvements be made?
* Efficacy and tolerability in diabetic neuropathy
* Efficacy in other indications

Dr. Christine Rauschkolb
Program Director/ Medical Scientist Pain- Clinical Development
Schwarz BioSciences

11:00 Morning Coffee

11:20 NAALADase Inhibition: a Novel Mechanism for Treating
Neuropathic Pain and Peripheral Neuropathy
* Selective Blockade of excitotoxic glutamate
* Efficacy in multiple animal models of peripheral neuropathy,
  neuropathic pain, stroke, and ALS
* Phase 1 trial results

Dr. Krystyna Wozniak
Lead Scientist on NAALADase Program
Guilford Pharmaceutical Inc

HEADACHE AND MIGRAINE PAIN- PRODUCT ANALYSIS

12:00 VIOXX - First Coxib Approved of Acute Migraine
* Migraine - a serious debilitating disorder
* Current acute migraine therapy
* Efficacy of rofecoxib in acute migraine therapy
* Safety of rofecoxib in acute migraine therapy
* Role of rofecoxib in acute migraine therapy

Dr. Tony Ho
Associate Director
Merck

12:40 Lunch

MARKET OPPORTUNITIES

14:00 CASE STUDY: The NanoCrystal Technology Approach
* How to overcome solubility issues for pain therapeutics
* Technology performance advantages
* Can it be used as a life cycle management tool?
* A commercialised, validated solution

Gary Liversidge
Senior Director, Project Planning and Management
Elan

14:40 CASE STUDY: Peptrans, a Novel Approach to Brain
Delivery
* The BBB and drug delivery in the CNS
* Pep:trans mechanism of action
* Delivery of analgesics- an effective solution?
* Potential within the market- where can you capture a share of
  the market?

Jamal Temsamani
Director, Preclinical R&D
Synt:em

15:20 Afternoon Tea

15:40 Cannabis Based Medicines- How to Optimise Pain
Treatment
* Clinical indication and pain management with cannabinoids
* GW cultivation license, possession and supply for medical
  research
* R&D clinical trials- quality, safety, efficacy and phase I-III trials
* Drug delivery technologies- oro mucosal sprays, oral
  formulations and inhalers
* Limitations of cannabinoid therapies- where can you fail?
* Case study: update on Sativex

Dr. Stephen Wright
Director of R&D
GW Pharma Ltd

16:20 Regulatory Limitations- Use and Distribution of Narcotic
Drugs
* Medical narcotics, the potential for misuse
* The prevention of drug abuse- new methods and control
* National drug policies- updates and how to enforce them
* Control of substances- how it limits availability for
  legitimate use

Dr. Mike Reed
Director Branded Product Marketing International
Alpharma

17:00 Generics: Identifying and Overcoming the Legal and
Regulatory Challenges of the Future
* The latest developments affecting the generic drug sector and
  pharmaceutical legislation
* Important legal issues- current scientific initiatives
* Potential solutions to current challenges
* Key regulatory issues in Europe

Mr. Horst Kastrup
VP Worldwide Regulatory Affairs
Viatris

17:40 Questions and Discussion

18:00 Chairman summation

18:10 Close of Conference





Terms & Conditions
NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below.
Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes, which are available on the day, will be sent to you. Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries.

Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses.

To unsubscribe please reply with unsubscribe in the subject line. 

Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. If you wish your details to be amended, please send your request to the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG. Alternatively please reply with unsubscribe in the subject line. Please allow approximately 7 days for your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes come into effect.






























  
#####################################################################################

This email has been scanned by MailMarshal, an email content filter. 

#####################################################################################